USA flag logo/image

An Official Website of the United States Government

Identification of microRNA Biomarkers for Colon Cancer Recurrence Risk…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R44CA138038
Solicitation Year:
2011
Solicitation Topic Code:
NCI
Solicitation Number:
PA09-080
Small Business Information
ASURAGEN, INC.
2150 WOODWARD STREET SUITE 100 AUSTIN, TX 78744-1840
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2011
Title: Identification of microRNA Biomarkers for Colon Cancer Recurrence Risk Stratifica
Agency: HHS
Contract: 4R44CA138038-03
Award Amount: $956,372.00
 

Abstract:

DESCRIPTION (provided by applicant): The current primary form of treatment for all stages of colon cancer is surgical resection, with overall survival rates depending upon whether the cancer recurs and metastasizes. The likelihood of recurrence is directlyrelated to the stage of cancer, which is determined by the depth of tumor penetration into the wall of the colon. Recurrence rates range from 20% in stage I, up to 40% in stage II patients and up to 60% in stage III patients. However, colon cancer stagingis not an accurate method for predicting recurrence. In fact, all existing approaches to postoperative surveillance of patients with colon cancer are inadequate because disease recurrence is only detected when interventions have relatively little benefiton patient survival. Several prognostic markers have been proposed but because of a lack of specificity and sensitivity these have not been approved for use as clinical markers. New colon cancer markers that could accurately predict recurrence would be valuable for identifying patients that are at risk of cancer and may benefit from adjuvant therapy shortly after resection. The long-term goal for this project is to develop a molecular diagnostic assay that can be used at the time of resection of a primary colon tumor to identify patients with a high risk of recurrence. We will focus on microRNA (miRNA) biomarkers in these studies. Within the last two decades there has been great interest in miRNAs, which are noncoding small RNAs that have been initially identified as regulators of development, and have more recently been demonstrated to have a role in a number of cancers. Additionally, miRNA expression patterns have been shown to be highly predictive of cancer type, making them ideal as prognostic indicators.Our preliminary investigations have revealed miRNAs that are highly predictive of recurrence, but these studies need to be validated and expanded. We will utilize a comprehensive miRNA expression profiling system to the expanded miRNA discovery and buildbiomarker sets for prediction of recurrence of CRC. Bioinformatics analyses will be used to establish prognostic indices with high performance in predicting recurrence. In phase II we will implement design features on the validated biomarker set to developa robust, reliable, and reproducible qRT-PCR assay for miRNA analysis. We anticipate that our studies will be the foundation for a comprehensive clinical test to assist physicians and patients in the management of colon cancer recurrence. PUBLIC HEALTH RELEVANCE: Resection of colon cancer is often not effective because patients with significantly advanced disease have a high likelihood of recurrence and metastasis. Our long term goal is to develop a prognostic assay for colon cancer recurrence thatwill improve clinical management of colon cancer by identifying patients prior to clinical manifestation of recurrence, and at a stage at which medical intervention may benefit the patient.

Principal Investigator:

Elizabeth Mambo
512-651-0200
emambo@asuragen.com

Business Contact:

Annette Schlageter
512-681-5367
aschlageter@asuragen.com
Small Business Information at Submission:

ASURAGEN, INC.
2150 WOODWARD STREET SUITE 100 AUSTIN, TX 78744-1840

EIN/Tax ID: 120416752
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No